Brief: Adamis Pharmaceuticals Corp Says Preparing To Begin Patient Enrollment In A Phase 2/3 Clinical Trial To Evaluate Use Of Tempol In Patients With Covid-19

DMK Pharmaceuticals

01/06/2021 14:06

June 1 (Reuters) - Adamis Pharmaceuticals Corp  ADMP.O :
    * ADAMIS PHARMACEUTICALS CORP - PREPARING TO BEGIN PATIENT
ENROLLMENT IN A PHASE 2/3 CLINICAL TRIAL TO EVALUATE USE OF
TEMPOL IN PATIENTS WITH COVID-19
    * ADAMIS PHARMACEUTICALS CORP - BASED ON DISCUSSIONS AND
FEEDBACK
FROM U.S. FDA, CO RESUBMITTED ITS NDA FOR ZIMHI IN MAY

Source text for Eikon:  ID:nGNX4mgr2t 
Further company coverage:  ADMP.O 

 ((reuters.briefs@thomsonreuters.com;))